The acquisition fundamentally changes Aspire's revenue profile, but integration risk and debt service on the $22.5M facility are key watchpoints. Monitor upcoming quarterly filings for DCS's audited financials and combined cash flow. The convertible note's $8.00 conversion price is well above current levels, limiting near-term dilution but creating overhang if shares appreciate.
Price Chart
Executive Summary
Aspire Biopharma completed its acquisition of Dura Driver Control Systems (DCS) for approximately $30M in cash, funded by a $22.5M senior secured revolving credit facility and cash on hand. DCS generated $209.5M revenue and $22.3M Adjusted EBITDA in FY2025, transforming Aspire from a pre-revenue biotech into a diversified enterprise with immediate scale. Separately, Aspire issued $3.75M principal amount of secured convertible notes (20% OID, net $3M) to fund working capital, adding modest dilution at an $8.00 conversion price.
Key Financial Metrics
Key Facts
- Acquisition of Dura Driver Control Systems closed for approximately $30M in cash
- DCS FY2025 revenue of $209.5M and Adjusted EBITDA of $22.3M (unaudited)
- DCS H1 2026 revenue of $103.9M and Adjusted EBITDA of $10.5M (unaudited)
- Aspire entered a $22.5M senior secured revolving credit facility to fund the acquisition
- Issued $3.75M principal amount of secured convertible notes at $8.00/share conversion price, netting $3M after 20% OID
- Convertible notes mature in 6 months with optional extensions; proceeds for working capital
Financial Impact
Transformative revenue addition: DCS adds ~$200M+ annual revenue vs Aspire's pre-acquisition $10M market cap; $30M cash acquisition funded by $22.5M credit facility and cash; $3M net convertible note proceeds for working capital
Risk Factors
- Integration of DCS's 11 global manufacturing facilities and 50+ customer relationships
- Debt service on $22.5M revolving credit facility; potential covenant compliance issues
- Convertible note dilution if converted (468,750 shares at $8.00, but capped at 19.99% of outstanding per Nasdaq rules)
- DCS's automotive industry cyclicality and exposure to OEM demand
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036777 |
| Exhibit: ex10-4.htm | 0001493152-26-036777 |
| Exhibit: ex99-1.htm | 0001493152-26-036777 |
| Exhibit: ex10-2.htm | 0001493152-26-036777 |
| Document: form8-k.htm | 0001493152-26-036777 |
| Document: 0001493152-26-036777-index-headers.html | 0001493152-26-036777 |
| Document: 0001493152-26-036777-index.html | 0001493152-26-036777 |
| Document: 0001493152-26-036777.txt | 0001493152-26-036777 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K/A | $8.85 | awaiting T+20 | — | $8.44 (−4.63%) |
Aug 19, 2026 9w ago | 8-K | $7.90 $9.12 | ▲ +15.44% | ▲ +17.39% | $8.44 (+6.84%) |
Aug 10, 2026 11w ago | 8-K | $7.79 $8.85 | ▲ +13.61% | ▲ +14.52% | $8.44 (+8.34%) |
Jul 20, 2026 14w ago | 8-K | $7.54 $7.64 | ▲ +1.33% | ▼ −1.24% | $8.44 (+11.94%) |
Jun 12, 2026 19w ago | 8-K | $4.96 $6.01 | ▲ +21.17% | ▲ +19.39% | $8.44 (+70.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers